

AMENDMENTS TO THE CLAIMS:

The following listing of claims replaces all prior versions of claims in this application.

1. (currently amended) A method ~~Use of an alpha2-adrenoceptor antagonist in the manufacture of a medicament for inhibiting the development of epilepsy, which comprises administering an effective amount of an alpha2-adrenoceptor antagonist to in~~
a patient at risk of developing epilepsy.
2. (currently amended) The method according to claim 1, wherein the alpha2-adrenoceptor antagonist is atipamezole or a pharmaceutically acceptable salt thereof.
3. (currently amended) The method according to claim 1, wherein the alpha2-adrenoceptor antagonist is idazoxan or a pharmaceutically acceptable salt thereof.
4. (currently amended) The method according to claim 1, wherein the alpha2-adrenoceptor antagonist is efaroxan or a pharmaceutically acceptable salt thereof.
5. (currently amended) The method according to claim 1, wherein the alpha2-adrenoceptor antagonist is 4-(2-ethyl-5-fluoro-2,3-dihydro-1H-inden-2-yl)-1H-imidazole or a pharmaceutically acceptable salt thereof.
6. (currently amended) The method according to claim 1, wherein the alpha2-adrenoceptor antagonist is an analog chosen from analogs of atipamezole, analogs of idazoxan, and analogs of efaroxan.

7. (currently amended) The method~~use~~ according to claim 1, wherein said risk of developing epilepsy is caused by head trauma, brain ischemia, infection, or neurosurgical operation.